Blueprint Medicines Corp Stock Probability of Future Stock Price Finishing Under 96.53
| BPMC Stock | USD 92.47 0.11 0.12% |
Blueprint |
Blueprint Medicines Target Price Odds to finish below 96.53
The tendency of Blueprint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 96.53 after 90 days |
| 92.47 | 90 days | 96.53 | about 87.01 |
Based on a normal probability distribution, the odds of Blueprint Medicines to stay under $ 96.53 after 90 days from now is about 87.01 (This Blueprint Medicines Corp probability density function shows the probability of Blueprint Stock to fall within a particular range of prices over 90 days) . Probability of Blueprint Medicines Corp price to stay between its current price of $ 92.47 and $ 96.53 at the end of the 90-day period is about 26.25 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.05 suggesting Blueprint Medicines Corp market returns are highly-sensitive to returns on the market. As the market goes up or down, Blueprint Medicines is expected to follow. Additionally Blueprint Medicines Corp has an alpha of 0.014, implying that it can generate a 0.014 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Blueprint Medicines Price Density |
| Price |
Predictive Modules for Blueprint Medicines
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Blueprint Medicines Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Blueprint Medicines Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Blueprint Medicines is not an exception. The market had few large corrections towards the Blueprint Medicines' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Blueprint Medicines Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Blueprint Medicines within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | 1.05 | |
σ | Overall volatility | 4.74 | |
Ir | Information ratio | 0.01 |
Blueprint Medicines Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Blueprint Medicines for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Blueprint Medicines Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 249.38 M. Net Loss for the year was (506.98 M) with profit before overhead, payroll, taxes, and interest of 177.28 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Blueprint Medicines SWOT analysis stock outlook amid Ayvakit success |
Blueprint Medicines Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Blueprint Stock often depends not only on the future outlook of the current and potential Blueprint Medicines' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Blueprint Medicines' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.6 M | |
| Cash And Short Term Investments | 710.6 M |
Blueprint Medicines Technical Analysis
Blueprint Medicines' future price can be derived by breaking down and analyzing its technical indicators over time. Blueprint Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Blueprint Medicines Corp. In general, you should focus on analyzing Blueprint Stock price patterns and their correlations with different microeconomic environments and drivers.
Blueprint Medicines Predictive Forecast Models
Blueprint Medicines' time-series forecasting models is one of many Blueprint Medicines' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Blueprint Medicines' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Blueprint Medicines Corp
Checking the ongoing alerts about Blueprint Medicines for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Blueprint Medicines Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the previous year's revenue of 249.38 M. Net Loss for the year was (506.98 M) with profit before overhead, payroll, taxes, and interest of 177.28 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Blueprint Medicines SWOT analysis stock outlook amid Ayvakit success |
Check out Blueprint Medicines Backtesting, Blueprint Medicines Valuation, Blueprint Medicines Correlation, Blueprint Medicines Hype Analysis, Blueprint Medicines Volatility, Blueprint Medicines History as well as Blueprint Medicines Performance. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.